Corporate Presentations Eledon Corporate Presentation ALS Phase 2a Clinical Trial Update Presentation Eledon Pharmaceuticals R&D Day Presentation Scientific Presentations 2021 International Pancreas and Islet Transplantation Association Congress A Phase 2 Safety and Tolerability Study of an Anti CD40L Antibody, AT-1501 in Adults with ALS 2021 American Transplant Congress The Development and Characterization of AT-1501, an Anti-CD40L Antibody Lacking Fc Effector Function Pharmacokinetic and Toxicity Studies of an Anti-CD40L Antibody, AT-1501 in Rhesus Macaques CSS